Point-Of-Care Body Fluid Diagnostics in Microliter

Total Page:16

File Type:pdf, Size:1020Kb

Point-Of-Care Body Fluid Diagnostics in Microliter POINT-OF-CARE BODY FLUID DIAGNOSTICS IN MICROLITER SAMPLES by LINUS TZU-HSIANG KAO Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Dissertation Adviser: Dr. Miklós Gratzl Department of Biomedical Engineering CASE WESTERN RESERVE UNIVERSITY May 2009 CASE WESTERN RESERVE UNIVERSITY SCHOOLA OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Linus Tzu-Hsiang Kao candidate for the Ph.D. degree *. (signed) Miklos Gratzl (chair of the committee) Clive Hamlin Uziel Landau Andrew Rollins Christian Zorman (date) March 19, 2009 *We also certify that written approval has been obtained for any proprietary material contained therein. Dedication To my parents and my wife, Yu-Ting Lin, for their love and support Table of Contents Table of Contents 1 List of Tables 7 List of Figures 8 Abstract 10 Chapter 1. Introduction of Point-of-Care Testing, Clinical Enzymology, and Electrochemical Enzyme Assays 12 1.1. Introduction 13 1.2. Point-of-Care Testing 14 1.2.1. Current state-of-the-art 17 1.3. Fundamentals of Enzymology 19 1.3.1. Significance of clinical enzyme analysis 21 1.3.2. Enzyme Kinetics 22 1.3.3. Units for enzyme activity 24 1.3.4. Factors affect enzyme kinetics 25 1.4. Enzyme Assays 26 1.4.1. Continuous assay 28 1.4.2. Discontinuous assay 28 1 1.4.3. Coupled assay 30 1.5. Principles of Developing Electrochemical pH-stat for Point-of-Care Testing 31 1.5.1. Conventional pH-stat versus electrochemical pH-stat 32 1.5.2. Electrochemical pH-stat on Rotating Sample System (RSS) 33 1.5.3. Limitations 35 1.6. Conclusion 36 1.7. References 39 Chapter 2. Ragentless pH-stat for Microliter Fluid Specimens 45 2.1. Abstract 46 2.2. Introduction 47 2.3. Experimental 52 2.3.1. Apparatus 52 2.3.2. Materials 54 2.3.3. Procedures 55 2.4. Results and Discussion 57 2.4.1. System characteristics 57 2.4.2. Current efficiency 59 2.4.3. Determination of AChE activity 60 2 2.5. Conclusions 63 2.6. Acknowledgements 64 2.7. References 65 Chapter 3. Determination of Critical Micelle Concentration with the Rotating Sample System 70 3.1. Abstract 71 3.2. Introduction 72 3.3. Experimental 76 3.3.1. Materials 76 3.3.2. Apparatus 76 3.3.3. Procedures 77 3.4. Results and Discussion 78 3.5. Conclusions 86 3.6. Acknowledgement 86 3.7. References 87 Chapter 4. Serum Cholinesterase Assay Using a Reagent-free Micro pH-stat 90 4.1. Abstract 91 3 4.2. Introduction 92 4.3. Experimental 96 4.3.1. Materials 96 4.3.2. Apparatus 97 4.3.3. Procedures 97 4.4. Results and Discussion 99 4.4.1. Current efficiency of the electrochemical micro pH-stat in fetal bovine serum 99 4.4.2. Effect of sample dilution on current efficiency 100 4.4.3. Determination of ChE enzyme activities in fetal bovine serum with electrochemical pH-stating 102 4.4.4. Determination of ChE activity in human serum with electrochemical pH-stating 105 4.5. Conclusions 105 4.6. Acknowledgements 106 4.7. References 107 Chapter 5. Conclusions and Future Work 110 5.1. Summary 111 4 5.1.1. Proof of concept: electrochemical micro pH-stat 112 5.1.2. Application of electrochemical micro pH-stat in biological samples 113 5.1.3. RSS for determination of Critical Micelle Concentration 114 5.2. Future Work 115 5.2.1. Microfabricated pH-stat chip 115 5.2.2. Measurement of substrate concentration and buffer capacity 117 5.2.3. NADH-based enzyme assay 118 5.3. References 121 Appendix I. Characteristics of the Reagent-Free Micro pH-stat System 125 A-I.1. Schematics of the Reagent-Free Micro pH-stat 125 A-I.2. Current generating circuit and voltage isolation 126 A-I.3. PID control algorithm 128 A-I.4. Chamber for pH-stat on the RSS 130 A-I.5. Elimination of CO2 interference 132 A-I.6. Minimizing the effect of protein adsorption at the liquid-air interface 133 A-I.7. Micro pH electrode 135 A-I.8. Implementation of the advanced PID control 137 A-I.9. Reference 140 5 Appendix II. Possible errors during pH-stating and the trouble-shooting procedures 141 A- II.1. Background pH drift 141 A- II.2. Erratic pH-stating 142 A- II.3. Reference 143 Bibliography 144 6 List of Tables TABLE 1.1. Enzymes of clinical importance that can be analyzed by pH-stating 38 TABLE 2.1. Current efficiency of the micro pH-stat in KNO3 buffer 60 7 List of Figures FIGURE 1.1. Comparison of the clinical testing process in an outpatient situation between the central laboratory and POCT methods 16 FIGURE 1.2. Urea cycle: the primary mechanism for disposal of waste nitrogen resulted from protein turnover and dietary intake 20 FIGURE 1.3. Michaelis-Menten Kinetics 24 FIGURE 1.4. Initial rate measurement of enzyme kinetics 27 FIGURE 1.5. Schematic diagram of the Rotating Sample System 35 FIGURE 2.1. Schematic diagram of the reagentless micro pH-stat based on the Rotating Sample System platform (RSS) 51 FIGURE 2.2. Substrate dependence of AChE activity determined with the micro pH-stat and with spectrophotometry as control 62 FIGURE 2.3. pH dependence of AChE activity 63 FIGURE 3.1. Schematic view of the Rotating Sample System used for CMC detection 74 FIGURE 3.2. Cyclic voltammograms of 25 mM K4[FeCN6] at the CMC of Triton X-100 (140 ppm) 79 FIGURE 3.3. Normalized cyclic voltammetry currents of 25 mM K4[FeCN6] 84 FIGURE 4.1. Schematic of the electrochemical micro pH-stat built on the Rotating Sample System platform 95 8 FIGURE 4.2. Effect of enzyme dilution on the enzyme activity as determined with the micro pH-stat 101 FIGURE 4.3. Comparison of ChE activities in FBS measured with the electrochemical micro pH-stat and with the standard optical assay using Ellman’s reagent 104 FIGURE 5.1. Prototype of microfluidic pH-stat chip 116 FIGURE 5.2. Schematics of lactate dehydrogenase assay using PB modified electrode 120 FIGURE A.1. Schematics of the pH-stat system 125 FIGURE A.2. Voltage controlled variable current source 126 FIGURE A.3. RS-232 optical-isolator 127 FIGURE A.4. The first version of LabVIEW controller 129 FIGURE A.5. Performance of PID controller 130 FIGURE A.6. Acrylic chamber with DI water channels surrounding the RSS cell and air jets housing 131 FIGURE A.7. Sample pH drift due to CO2 influx 133 FIGURE A.8. Protein adsorption in RSS sample 134 FIGURE A.9. Micro pH electrode 136 FIGURE A.10. Typical operation of the pH-stating assay for enzyme kinetics 139 9 Point-of-Care Body Fluid Diagnostics in Microliter Samples Abstract by LINUS TZU-HSIANG KAO Abstract Point-of-care testing (POCT) generally refers to the implementation of laboratory tests near the patient with the goal to minimize turnaround time, reduce medical cost, and improve medical outcome. The aim of this research is to develop, validate, and optimize a preliminary POCT system for body fluid diagnostics using our existing analytical platform, Rotating Sample System (RSS). The RSS is a convective platform for different optical and electrochemical analyses in microliter-sized samples. In this work we have developed a reagent-free electrochemical micro pH-stat for in vitro enzyme assays where a titrant of acid or base is produced by water electrolysis on the RSS platform. As water electrolysis induces no volume change and the current that generates the reagent can be precisely measured even at low levels, very small samples in 10 the 1-20 μL volume range become accessible for pH-stating: a reduction of more than an order of magnitude in specimen size relative to the most conventional methods. More importantly, analysis using untreated biological sample is feasible as turbidity would not influence pH-stat measurement. The RSS micro pH-stat effectively operates as a galvanostat with an output range of ±0.1-100 μA and can withstand sample impedance up to 100 kΩ. The cathodic current efficiency is virtually 100% in both buffer and serum samples. Results of cholinesterase activities in both buffer and serum using the proposed reagent-free pH-stat have been validated with standard optical techniques (r2 ≥ 0.97). This novel technique hence has great potential to become a miniaturized analyzer for point-of-care diagnostics. 11 Chapter 1 Introduction of Point-of-Care Testing, Clinical Enzymology, and Electrochemical Enzyme Assays Linus Tzu-Hsiang Kao Department of Biomedical Engineering Case Western Reserve University, Cleveland, Ohio 44106 12 1.1. Introduction Rudimentary point-of-care testing (POCT) was described as early as 1883 in London (Kiechle 2002). POCT generally refers to the implementation of laboratory tests near the patient’s bedside or at the “point of care" with the goal to minimize turnaround time, reduce medical cost, and improve patient management. Due to its potential to reshape the delivery of medical service, POCT is an emerging modality growing rapidly in the healthcare field. Our long term goal is to develop a portable point-of-care device for an array of body fluid analyses to aid biomedical research and expedite clinical diagnostics. The aim of this thesis is to develop, validate, and optimize a preliminary POCT platform using reagent-free micro pH-stating techniques for universal enzymatic analysis in body fluids. Body fluids such as blood continuously circulate throughout the body, delivering nutrients to cells and transporting products from and toward tissues.
Recommended publications
  • Vii. Infection Prevention
    VII. INFECTION PREVENTION Prevention of Hospital Acquired Infections What is Infection Prevention? Infection prevention is doing everything possible to prevent the spread of germs which lead to hospital acquired infection. What is a bloodborne pathogen? • Bloodborne pathogens are micro-organisms such as viruses or bacteria that are present in human blood that can cause disease in humans. These pathogens include, but are not limited to: – Hepatitis B (HBV) – Hepatitis C (HCV) – Human immuno-deficiency virus (HIV) – Malaria, syphilis, West Nile virus, Ebola OTHER POTENTIALLY INFECTIOUS MATERIAL (OPIM) • In addition to human blood, bloodborne pathogens can be found in other potentially infectious material such as: – Blood products (plasma/serum) – Saliva – Semen – Vaginal secretions – Skin tissue/cell cultures – Any body fluid that is contaminated with blood • Body fluids that are not usually considered infectious with bloodborne pathogens are: – Vomit – Tears – Sweat – Urine – Feces – Sputum /nasal secretions ALL BODY FLUIDS SHOULD BE REGARDED AS POTENTIALLY INFECTIOUS!!! TRANSMISSION IN THE WORKPLACE Bloodborne pathogens can be transmitted when blood or OPIM is introduced into the blood stream of a person • This can happen through: – Non intact skin (acne, scratches, cuts, bites, blisters, wounds) – Contact with mucus membranes found in the eyes, nose and mouth – Contaminated instruments such as needles and sharps METHODS TO PREVENT BLOODBORNE PATHOGEN EXPOSURE A. Standard Precautions – ALL body fluids should be considered as potentially infectious materials – Use stand precautions EVERY TIME you anticipate contact with blood, body fluids, secretions/excretions, broken skin and mucous membranes – Use appropriate personal protective equipment – Decontaminate spills METHODS TO PREVENT BLOODBORNE PATHOGEN EXPOSURE B. Personal Protective Equipment Include: gloves, gowns, laboratory coats, face shields or masks, eye protection, mouthpieces, resuscitation bags, pocket masks, or other ventilation devices.
    [Show full text]
  • Body Fluid Exposure Procedure
    Employee Health Services 210 Lincoln Street Worcester, MA 01605 Body Fluid Exposure Procedure Step 1: Treat Exposure Site As soon as possible after exposure, use soap and water to wash areas exposed to potentially infectious fluids Flush exposed mucous membranes with water Flush exposed eyes with 500 ml of water or saline, at least 3-5 minutes Do not apply caustic agents, disinfectants or antibiotics in the wound Step 2: Gather Information and Document Employees need to complete a “First Report of Injury” form, state or clinical, as appropriate. Students need to complete an occurrence form. Using the UMMHC PEEP sheet as a guide, document o The circumstances of the occupational exposure o Evaluation of the employee . Evaluation of exposure site . Evaluation of Hepatitis B, C and HIV status Hepatitis B antibody (HBA) Hepatitis B antigen (HSA) Hepatitis C antibody (HCV) HIV antibody . Baseline lab. At the initial visit, we do not necessarily know the disease status of the source patient. Therefore, the baseline labs take into account only the decision to take or decline PEP. No Post-Exposure Prophylaxis (PEP) [2 gold top tubes] Alt HSA HBA HCV HIV Taking Post-Exposure Prophylaxis 2 gold top and 1 purple top tubes All of the above, PLUS AST Amylase Creatinine Glucose CBC/diff UCG as appropriate o Evaluation of the source patient . When the source of the exposure is known Source chart needs to be reviewed and source consented for HIV, Hepatitis B antigen and antibody, and Hepatitis C. J: Employee Health: Body Fluid Exposure Procedure-Revised 09/29/09 jc 1 On the University campus, notify Pat Pehl, the HIV counselor.
    [Show full text]
  • Persistence of Ebola Virus in Various Body Fluids During Convalescence
    Epidemiol. Infect. (2016), 144, 1652–1660. © Cambridge University Press 2016 doi:10.1017/S0950268816000054 Persistence of Ebola virus in various body fluids during convalescence: evidence and implications for disease transmission and control A. A. CHUGHTAI*, M. BARNES AND C. R. MACINTYRE School of Public Health and Community Medicine, Faculty of Medicine, University of New South Wales, Sydney, Australia Received 19 November 2015; Final revision 22 December 2015; Accepted 6 January 2016; first published online 25 January 2016 SUMMARY The aim of this study was to review the current evidence regarding the persistence of Ebola virus (EBOV) in various body fluids during convalescence and discuss its implication on disease transmission and control. We conducted a systematic review and searched articles from Medline and EMBASE using key words. We included studies that examined the persistence of EBOV in various body fluids during the convalescent phase. Twelve studies examined the persistence of EBOV in body fluids, with around 800 specimens tested in total. Available evidence suggests that EBOV can persist in some body fluids after clinical recovery and clearance of virus from the blood. EBOV has been isolated from semen, aqueous humor, urine and breast milk 82, 63, 26 and 15 days after onset of illness, respectively. Viral RNA has been detectable in semen (day 272), aqueous humor (day 63), sweat (day 40), urine (day 30), vaginal secretions (day 33), conjunctival fluid (day 22), faeces (day 19) and breast milk (day 17). Given high case fatality and uncertainties around the transmission characteristics, patients should be considered potentially infectious for a period of time after immediate clinical recovery.
    [Show full text]
  • Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, [email protected]
    University of South Florida Scholar Commons Graduate Theses and Dissertations Graduate School July 2017 Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, [email protected] Follow this and additional works at: http://scholarcommons.usf.edu/etd Part of the Pathology Commons Scholar Commons Citation Mohamed, Mai, "Role of Amylase in Ovarian Cancer" (2017). Graduate Theses and Dissertations. http://scholarcommons.usf.edu/etd/6907 This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact [email protected]. Role of Amylase in Ovarian Cancer by Mai Mohamed A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Pathology and Cell Biology Morsani College of Medicine University of South Florida Major Professor: Patricia Kruk, Ph.D. Paula C. Bickford, Ph.D. Meera Nanjundan, Ph.D. Marzenna Wiranowska, Ph.D. Lauri Wright, Ph.D. Date of Approval: June 29, 2017 Keywords: ovarian cancer, amylase, computational analyses, glycocalyx, cellular invasion Copyright © 2017, Mai Mohamed Dedication This dissertation is dedicated to my parents, Ahmed and Fatma, who have always stressed the importance of education, and, throughout my education, have been my strongest source of encouragement and support. They always believed in me and I am eternally grateful to them. I would also like to thank my brothers, Mohamed and Hussien, and my sister, Mariam. I would also like to thank my husband, Ahmed.
    [Show full text]
  • Infection Control Orientation
    Infection Control: Preventing the Spread of Infectious Diseases Mount Sinai Hospital Healthcare-Associated Infections ~2 million hospital-acquired infections per year – These infections affect ~5-10% of patients. ~88,000 deaths related to those infections. At least 1/3 of those infections are preventable. Healthcare-Associated Infections (HAI) The most common HAI are: – Urinary tract infections (35%) – Surgical site infections (20%) – Bloodstream infections (15%) – Pneumonia (15%) Often associated with multidrug-resistant pathogens: MRSA, VRE, C. difficile, GNR (Klebsiella, Acinetobacter, etc.). Risk Factors for Healthcare- Associated Infections Severity of underlying illness Invasive devices and procedures Antimicrobial therapy Poor infection prevention practices – Healthcare worker hand hygiene – Environmental cleaning – Equipment disinfection and sterilization The Chain of Infection Pathogen Reservoir Susceptible Host where infectious agent normally lacks effective resistance lives and multiplies to pathogen Portal of Entry Portal of Exit entry sites, mechanisms by which mechanisms of introduction Mode of pathogen can leave reservoir Transmission contact, droplet, airborne, common vehicle, vector-borne Topics to be Covered Blood and Body Fluid Exposures (BBFE) – Definitions – Risk –Prevention – Post-exposure management Regulated Medical Waste Standard Precautions – Hand hygiene – Personal protective equipment Transmission-Based Precautions Bloodborne Pathogens Hepatitis B Hepatitis C Human Immunodeficiency Virus (HIV) Case 1 You are on your first rotation as a third year medical student. You want to be helpful to the nursing staff so you offer to empty Mr. Jones’ urinal. Unfortunately, you drop the urinal and your leg is splashed with clear, yellow urine. Case 2 You are now a seasoned fourth year student and you are performing phlebotomy on a 36 year old man admitted to the hospital with pneumonia.
    [Show full text]
  • Lipolytic Enzyme. Uses Thereof in the Food Industry
    (19) & (11) EP 2 267 107 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 29.12.2010 Bulletin 2010/52 C11B 3/00 (2006.01) A23J 7/00 (2006.01) C12N 9/20 (2006.01) (21) Application number: 10174040.5 (22) Date of filing: 18.07.2005 (84) Designated Contracting States: • Soe, Jørn AT BE BG CH CY CZ DE DK EE ES FI FR GB GR DK-8381, Tilst (DK) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Mikkelsen, Jørn SK TR DK-2650, Hvidovre (DK) • Povelainen, Mira (30) Priority: 16.07.2004 GB 0416035 FIN-00360, Helsinki (FI) 26.07.2004 US 591185 P • Pitkanen, Virve 07.07.2005 GB 0513859 02320 Espoo (FI) (83) Declaration under Rule 32(1) EPC (expert (74) Representative: Williams, Aylsa solution) D Young & Co LLP 120 Holborn (62) Document number(s) of the earlier application(s) in London EC1N 2DY (GB) accordance with Art. 76 EPC: 05773820.5 / 1 776 455 Remarks: This application was filed on 25-08-2010 as a (71) Applicant: Danisco A/S divisional application to the application mentioned 1001 Copenhagen K (DK) under INID code 62. (72) Inventors: • Miasnikov, Andrei 10160 Degerby (FI) (54) Lipolytic Enzyme. Uses Thereof In The Food Industry (57) The invention also encompases theuse of a lipo- a galactolipid to one or more acyl acceptor substrates, lytic enzyme obtainable from one of the following genera: wherein the enzyme is obtainable fromSteptomyces Streptomyces, Corynebacterium and Thermobifida in species and includes a lipolytic enzyme comprising an various methods and uses, wherein said lipolytic enzyme amino acid sequence as shown in SEQ ID No.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,962,800 B2 Mathur Et Al
    USOO89628OOB2 (12) United States Patent (10) Patent No.: US 8,962,800 B2 Mathur et al. (45) Date of Patent: Feb. 24, 2015 (54) NUCLEICACIDS AND PROTEINS AND USPC .......................................................... 530/350 METHODS FOR MAKING AND USING THEMI (58) Field of Classification Search None (75) Inventors: Eric J. Mathur, San Diego, CA (US); See application file for complete search history. Cathy Chang, San Diego, CA (US) (56) References Cited (73) Assignee: BP Corporation North America Inc., Naperville, IL (US) PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this Nolling etal (J. Bacteriol. 183: 4823 (2001).* patent is extended or adjusted under 35 Spencer et al., “Whole-Genome Sequence Variation among Multiple U.S.C. 154(b) by 0 days. Isolates of Pseudomonas aeruginosa J. Bacteriol. (2003) 185: 1316-1325. (21) Appl. No.: 13/400,365 2002.Database Sequence GenBank Accession No. BZ569932 Dec. 17. 1-1. Mount, Bioinformatics, Cold Spring Harbor Press, Cold Spring Har (22) Filed: Feb. 20, 2012 bor New York, 2001, pp. 382-393. O O Omiecinski et al., “Epoxide Hydrolase-Polymorphism and role in (65) Prior Publication Data toxicology” Toxicol. Lett. (2000) 1.12: 365-370. US 2012/O266329 A1 Oct. 18, 2012 * cited by examiner Related U.S. Application Data - - - Primary Examiner — James Martinell (62) Division of application No. 1 1/817,403, filed as (74) Attorney, Agent, or Firm — DLA Piper LLP (US) application No. PCT/US2006/007642 on Mar. 3, 2006, now Pat. No. 8,119,385. (57) ABSTRACT (60) Provisional application No. 60/658,984, filed on Mar. The invention provides polypeptides, including enzymes, 4, 2005.
    [Show full text]
  • The Role of Galactolipids in Spinach Chloroplast Lamellar Membranes: I
    Plant Physiol. (1974) 53, 699-704 The Role of Galactolipids in Spinach Chloroplast Lamellar Membranes I. PARTIAL PURIFICATION OF A BEAN LEAF GALACTOLIPID LIPASE AND ITS ACTION ON SUB- CHLOROPLAST PARTICLES" 2 Received for publication October 30, 1973 and in revised form January 3, 1974 MARK M. ANDERSON,' RICHARD E. MCCARTY, AND ELIZABETH A. ZIMMER Section of Biochemistry, Molecular and Cell Biology, Cornell University, Ithaca, New York 14850 ABSTRACT sis, such as fulfilling a structural requirement or even partici- pating directly in a reaction essential to photosynthesis. In an A galactolipid lipase has been isolated and partially purified effort to elucidate the possible role(s) of galactosyl diglycerides from the chloroplast fraction of the primary leaves of Phase- in photosynthesis, we isolated and partially purified a galacto- olus vulgaris var. Kentucky Wonder. The lipase hydrolyzed lipid lipase (galatosyl diglyceride acyl hydrolase) from primary monogalactosyl diglyceride rapidly and phosphatidyl choline bean leaf chloroplasts. The lipase was then used to deacylate relatively slowly. Triolein and p-nitrophenyl stearate were not the lipids in spinach chloroplasts and subchloroplast particles hydrolyzed. so that their ultrastructure and biochemical capabilities could Spinach subchloroplast particles were excellent substrates be determined as a function of galactolipid content. for the lipase. Initial rates of fatty acid release from sub- Galactolipase activity was first detected in extracts of Pha- chloroplast particles at 30 C by the lipase as high as 60 micro- seolus multifloris primary leaves by Sastry and Kates (19). equivalents per minute per milligram protein were observed. More recently Helmsing (9) has reported the purification of a At completion of the reaction, about 2.7 microequivalents of galactolipase from bean leaf homogenates.
    [Show full text]
  • Microalgal Enzymes with Biotechnological Applications
    marine drugs Review Microalgal Enzymes with Biotechnological Applications Giorgio Maria Vingiani 1, Pasquale De Luca 2 , Adrianna Ianora 1, Alan D.W. Dobson 3,4 and Chiara Lauritano 1,* 1 Marine Biotechnology Department, Stazione Zoologica Anton Dohrn, CAP80121 (NA) Villa Comunale, Italy 2 Research Infrastructure for Marine Biological Resources Department, Stazione Zoologica Anton Dohrn, CAP80121 (NA) Villa Comunale, Italy 3 School of Microbiology, University College Cork, College Road, T12 YN60 Cork, Ireland 4 Environmental Research Institute, University College Cork, Lee Road, T23XE10 Cork, Ireland * Correspondence: [email protected]; Tel.: +39-081-5833221 Received: 4 July 2019; Accepted: 1 August 2019; Published: 5 August 2019 Abstract: Enzymes are essential components of biological reactions and play important roles in the scaling and optimization of many industrial processes. Due to the growing commercial demand for new and more efficient enzymes to help further optimize these processes, many studies are now focusing their attention on more renewable and environmentally sustainable sources for the production of these enzymes. Microalgae are very promising from this perspective since they can be cultivated in photobioreactors, allowing the production of high biomass levels in a cost-efficient manner. This is reflected in the increased number of publications in this area, especially in the use of microalgae as a source of novel enzymes. In particular, various microalgal enzymes with different industrial applications (e.g., lipids and biofuel production, healthcare, and bioremediation) have been studied to date, and the modification of enzymatic sequences involved in lipid and carotenoid production has resulted in promising results. However, the entire biosynthetic pathways/systems leading to synthesis of potentially important bioactive compounds have in many cases yet to be fully characterized (e.g., for the synthesis of polyketides).
    [Show full text]
  • Ebola and Marburg Virus Disease Epidemics: Preparedness, Alert, Control and Evaluation
    EBOLA STRATEGY Ebola and Marburg virus disease epidemics: preparedness, alert, control and evaluation August 2014 © World Health Organization 2014. All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. WHO/HSE/PED/CED/2014.05 Contents Acknowledgements ............................................................................................................ 5 List of abbreviations and acronyms ................................................................................... 6 Chapter 1 – Introduction .................................................................................................... 7 1.1 Purpose of the document and target audience ....................................................................
    [Show full text]
  • Laboratory Orientation and Testing of Body Fluids and Tissues for Forensic Analysts
    Laboratory Orientation and Testing of Body Fluids and Tissues for Forensic Analysts This course is provided free of charge and is part of a series designed to teach about DNA and forensic DNA use and analysis. Find this course live, online at: http://dna.gov/training/forensicbiology Up dated: October 8, 2008 PPP RRR EEE SSS III DDD EEE NNN TTT ’’’ SSS DNA III N I T I A T I V E www.DNA.gov About this Course This PDF file has been created from the free, self-paced online course “Crime Scene and DNA Basics for Forensic Analysts.” To learn more and take this and other courses online, go to http://www.dna.gov/training/online-training/ . Most courses are free but you must first register at http://register.dna.gov . If you already are registered for any course on DNA.gov, you may login directly at the course URL, e.g., http://letraining.dna.gov or you can reach the courses by using the URL http://www.dna.gov/training and selecting the “ Login and view your courses” link. Questions? If you have any questions about this file or any of the courses or content on DNA.gov, visit us online at http://www.dna.gov/more/contactus/ . Links in this File Most courses from DNA.Gov contain animations, videos, downloadable documents and/or links to other useful Web sites. If you are using a printed, paper version of this course, you will not have access to those features. If you are viewing the course as a PDF file online, you may be able to use some of these features if you are connected to the Internet.
    [Show full text]
  • Chandran Et Al. Supporting Info.Pdf
    Supporting Information (SI) Appendix Part 1. Impact of tissue preparation, LMD, and RNA amplification on array output. p. 2 Text S1: Detailed Experimental Design and Methods Figure S1A: Correlation analysis indicates tissue preparation has minimal impact on ATH1 array output. Figure S1B: Correlation analysis indicates RNA degradation does not significantly impact array output. Figure S1C: Correlation analysis indicates two-round amplification does not significantly impact array output. Figure S1D: Independent biological replicates of LMD samples are highly correlated. Figure S1E: Validation of LMD array expression by qPCR. Table S1: Tissue preparation-associated genes Part 2. Analysis of LMD and parallel whole leaf array data. p. 13 Table S2A: Known PM-impacted genes enriched in LMD dataset Table S2B: Dataset of LMD and whole leaf genes with PM-altered expression Table S2C: LMD PM MapMan Results and Bins Table S2D: ics1 vs. WT LMD PM MapMan Results and Bins Table S2E: Infection site-specific changes for redox and calcium categories Table S2F: cis-acting regulatory element motif analysis Part 3. Process network construction p. 149 3A. Photosynthesis 3B. Cold/dehydration response Part 4. Powdery mildew infection of WT and myb3r4 mutants p. 173 Text S4: Detailed Experimental Design and Methods (supplement to manuscript) Figure S4A. Uninfected 4 week old WT and myb3r4 plants Figure S4B. myb3r4 mutants exhibit reduced visible PM growth and reproduction Figure S4C. PM-infected WT and myb3r4 mutants do not exhibit cell death Figure S4D. Endoreduplication occurs at site of PM infection not distal to infection Figure S4E. Ploidy correlates with nuclear size. Part 1. Impact of tissue preparation, LMD, and RNA amplification on array output.
    [Show full text]